DYRK1A and cancer: Given that the chronic conditions caused by high expression of DYRK1A, such as DS and AD, would require a long-term treatment with DYRK1A inhibitor drugs, it will be essential to evaluate the safety of these drugs given the emerging role of this kinase in cancer.